Rocket Lab stock jumps today despite $103 million CFO sale filing: what RKLB traders watch next
9 January 2026
1 min read

Rocket Lab stock jumps today despite $103 million CFO sale filing: what RKLB traders watch next

New York, Jan 9, 2026, 11:43 EST — Regular session

  • Rocket Lab shares were up about 4.6% in late morning trading after a volatile week.
  • SEC filings showed the CFO and COO sold shares under preset Rule 10b5-1 trading plans.
  • Next focus: the company’s next earnings update and any timetable changes for Neutron.

Rocket Lab Corp shares rose 4.6% to $86.87 in late morning trading on Friday, bouncing after a dip a day earlier as investors weighed heavy insider selling disclosed in regulatory filings. 1

The moves matter because Rocket Lab’s rally into year-end has made the stock sensitive to supply — and headlines — when top executives sell. Shares had fallen 1.2% on Thursday to $83.08, after touching $82.26, MarketBeat data showed.

A Form 4 filing showed Chief Financial Officer Adam C. Spice sold 1,365,665 shares on Jan. 5 at weighted-average prices between $72.149 and $78.0435, transactions that add up to about $103.1 million. The filing also showed Spice exercised options to buy 731,330 shares at $1.09, and marked the sales as part of a Rule 10b5-1 plan — a preset instruction that allows insiders to trade automatically. 2

A separate Form 4 showed Chief Operating Officer Frank Klein sold 100,000 shares on Jan. 2 at weighted-average prices ranging from $67.6104 to $75.8002, for about $7.3 million. That sale also flagged a Rule 10b5-1 plan adopted on Sept. 19, the filing showed. 3

Rocket Lab’s stock has surged since December after it won a contract worth up to $805 million from the U.S. Space Development Agency, pushing the company deeper into U.S. national-security work. “We are very encouraged by this contract decision,” Cantor Fitzgerald analyst Andres Sheppard wrote in a Dec. 19 note. 4

Needham raised its price target on Rocket Lab to $90 from $63 after the SDA award, pointing to the company’s growing defense footprint, Investors.com reported. The firm has also talked up 2026 expansion plans and a first flight for its Neutron rocket, a larger launcher aimed at a broader market than Electron.

But the stock’s speed cuts both ways. Rocket Lab has a high beta — a measure of how sharply a stock tends to swing versus the broader market — and it remains unprofitable, leaving little room for delays on Neutron or stumbles delivering on large government programs. 5

Next up is the company’s next quarterly report: market calendars peg Rocket Lab’s next earnings date at Feb. 26. Traders will be listening for any changes to the Neutron schedule, margins, and how fast contract backlog turns into revenue.

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Liquidia stock jumps nearly 15% after Yutrepia sales update, cash-flow claim
Previous Story

Liquidia stock jumps nearly 15% after Yutrepia sales update, cash-flow claim

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026
Next Story

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

Go toTop